- BioPharm International-06-01-2003
- Volume 16
- Issue 6
SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You
by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.
Articles in this issue
over 22 years ago
Inside Washington: Reshaping Biotech Drug Developmentover 22 years ago
BioTrends: M&A MalaiseNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.